
News|Articles|February 1, 2011
FDA Pipeline Preview, February 2011 (Afrezza, Nuvigil, Opana ER, Liprotamase, Erwinaze, Telaprevir, SNS01-T, XL184, QLT091001, Fidaxomicin)
Recent FDA action (through, January 2011) related to Afrezza, Nuvigil, Opana ER, Liprotamase, Erwinaze, Telaprevir, SNS01-T, XL184, QLT091001, Fidaxomicin.
Advertisement
Complete response
Not recommended for approval
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Cobenfy in Practice: Hope, Hurdles, and the Next Chapter in Schizophrenia Care
2
FDA Approves Gazyva for Lupus Nephritis in Adults
3
AI in Ophthalmology: The Key to the Present Success Includes a CPT Code. The Future? Agentic AI That Doesn’t Wait To Be Told What To Do | AAO 2025
4
What’s New in the Diagnosis and Treatment of Headaches That Ophthalmologists Should Know About? | AAO 2025
5